Project Grant HT94252310690
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $1,508,132 to the University of Rhode Island Research Office through the Military Medical Research and Development program (CFDA 12.420) to conduct research on the use of bile acid-binding resins to decrease systemic per- and polyfluoroalkyl substance (PFAS) levels and improve serum lipid profiles in veterans. The four-year project, initiated on September 30, 2025 and scheduled for completion by September 29, 2029,...
- Federal Project Grant Summary The University of Washington's Office of Sponsored Programs received a $769,887 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), awarded May 15, 2026, with a completion date of May 14, 2029. The grant funds research entitled "Preventing PFAS Neurotoxicity Through Folate Pathway Intervention," which investigates medical solutions addressing the neurotoxic effects of per- and...
- Federal Grant Award Summary The University of Louisville's Office of Research & Innovation received a $1.29M project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to investigate the use of bile acid-binding resins as a therapeutic intervention to reduce systemic per- and polyfluoroalkyl substance (PFAS) levels and improve serum lipid profiles in veterans. The four-year research initiative, funded through September 29, 2029,...
- Federal Grant Award Summary The Defense Health Agency awarded $715,213 under the Military Medical Research and Development program (CFDA 12.420) to Veterans Education and Research Association of Northern New England, Inc. (VERANNE) on September 30, 2025, with completion anticipated by September 29, 2029. The project, titled "Use of Bile Acid-Binding Resins to Decrease Systemic Per- and Polyfluoroalkyl Substance (PFAS) Levels and Improve Serum Lipid Profiles in Veterans," will be...
- Federal Grant Award Summary The Defense Health Agency awarded The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. a $648,097 project grant under the Military Medical Research and Development program (CFDA 12.420) for research investigating per- and polyfluoroalkyl substances (PFAS) and risks of thyroid cancer among active component service members of the U.S. Military. The three-year award, effective September 1, 2025 through August 31, 2028, supports hypothesis-driven...
- Carnegie Mellon University received a $660,283 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for a three-year period beginning August 1, 2025. The award supports research on "Prioritizing Bioaccumulative Per/Polyfluoroalkyl Substances (PFAS) in Complex Mixtures: A High-Throughput Bioanalytical and Machine Learning Approach," to be conducted at Carnegie Mellon's Pittsburgh, Pennsylvania campus through July 31,...
- The University of Illinois was awarded a $798,912 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research to investigate how PFAS (per- and polyfluoroalkyl substances) exposures can reprogram prostate stem cells and drive carcinogenesis and cancer progression. The 3-year project, running from July 1, 2023 to June 30, 2026, will advance scientific understanding of how environmental PFAS exposures may...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Metis Foundation a $864,533 Project Grant effective September 30, 2025, through September 29, 2028, under the Military Medical Research and Development program (CFDA 12.420). The award supports research investigating the relationship between per- and polyfluoroalkyl substances (PFAS) and other toxic military exposures with pancreatic cancer risk in military populations. Research will be conducted at the awardee's...
- Federal Grant Award Summary Purdue University received a $770K project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 30, 2026, with completion targeted for September 29, 2029. The award funds research examining the molecular mechanisms driving neurodegeneration resulting from Per- and Polyfluoroalkyl Substances (PFAS) exposure. This three-year research initiative will be conducted at Purdue's West...
- Federal Project Grant Award Summary The University of Illinois has been awarded $555,100 by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for a three-year project commencing August 1, 2025 and concluding July 31, 2028. The project, titled "Testicular Germ Cell Tumors as a Sentinel Cancer of PFAS Exposure," supports advanced biomedical research investigating the relationship between perfluoroalkyl and polyfluoroalkyl substances...
The Defense Health Agency awarded a $1,117,352 Project Grant to Trustees of Boston University's Boston University Medical Campus to develop a novel and practical intervention for detoxification of per- and polyfluoroalkyl substances (PFAS) in humans. The grant, funded under the Military Medical Research and Development program (CFDA 12.420), supports the university's research to transform health care for Service Members and the public through innovative biomedical research. As part of the project, the University of Massachusetts Lowell's Office of Research Administration-Lowell is serving as a sub-grantee, providing PFAS chemical analysis, biochemical analyses of gut inflammation and permeability markers, expertise in exposure and biomarker data analyses, and human nutrition expertise. This collaborative effort aims to investigate medical solutions for the battlefield and advance the understanding and treatment of PFAS exposure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.1m | 7/12/23 |